Arrowhead Pharmaceuticals (ARWR) is back in focus after new clinical data for plozasiran and ARO-INHBE, presented at recent scientific meetings, highlighted potential use in harder to treat patients and additional metabolic indications.
See our latest analysis for Arrowhead Pharmaceuticals.
The stock has gained clear momentum recently, with a 24.61% 90 day share price return and a very large 1 year total shareholder return, as clinical and commercial updates around plozasiran and ARO-INHBE keep investor attention on future trial and uptake milestones.
If positive RNAi data has caught your eye, this could be a good moment to see what else is moving in the space and scan the 33 healthcare AI stocks.
With Arrowhead now valued at about US$11.1b, trading at US$78.99 and showing an intrinsic value estimate that is 56% higher, investors have to ask: is this RNAi specialist still undervalued, or is the market already pricing in future growth?
Most Popular Narrative: 23.3% Overvalued
Arrowhead’s most followed narrative puts fair value at $64.08 per share, below the recent $78.99 close. Investors are weighing a premium price against ambitious assumptions.
Multiple large pharma collaborations and milestone generating partnerships (notably with Sarepta, Amgen, Takeda, and Sanofi) provide non dilutive capital, revenue diversity, and stability independent of volatile equity markets, supporting sustained R&D investments and improving medium term cash flow visibility.
Curious what kind of revenue path and margin profile would need to materialize to support this higher fair value, and how much earnings power is being built in over time.
Result: Fair Value of $64.08 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on complex Phase 3 readouts and partner milestones. Any delay, weak data, or collaboration reset could quickly cool optimism around the story.
Find out about the key risks to this Arrowhead Pharmaceuticals narrative.
Another Take on Value
So far the story has focused on a fair value of $64.08 that suggests Arrowhead is 23.3% overvalued. Our DCF model points the other way, with a future cash flow value of $179.12 per share versus a market price of $78.99. That represents a wide gap. Which story do you think is closer to reality?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Arrowhead Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Feeling torn between the bullish and cautious angles in this story is natural. Act while the facts are fresh and weigh both the 2 key rewards and 1 important warning sign
Looking for more investment ideas?
If Arrowhead has sharpened your interest in high quality opportunities, do not stop here. Broaden your watchlist now and give yourself more choices.
- Spot potential bargains before the crowd by scanning the 47 high quality undervalued stocks.
- Prioritise resilience and sleep easier at night by checking the 64 resilient stocks with low risk scores.
- Hunt for under followed potential with the screener containing 22 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com